# Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy

> **NCT03457142** · PHASE2 · TERMINATED · sponsor: **Roswell Park Cancer Institute** · enrollment: 15 (actual)

## Conditions studied

- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma

## Interventions

- **BIOLOGICAL:** Abatacept
- **DRUG:** Dexamethasone
- **DRUG:** Ixazomib Citrate
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT03457142
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-09-11
- **Primary completion:** 2022-11-21
- **Final completion:** 2024-11-06
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** funding ended
- **Last updated:** 2025-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03457142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03457142, "Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03457142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*